Health experts applaud SC ruling on Norvartis

Published: 01st April 2013 03:19 PM  |   Last Updated: 01st April 2013 04:41 PM   |  A+A-


Health experts welcomed the landmark ruling of the Supreme Court Monday, rejecting Swiss drugmaker Novartis AG's attempt to patent its cancer drug, saying the dictum would ensure that patients get access to cheaper life-saving drugs.

"This is a landmark judgment. This will have a long-term and wide impact, as the generic version makes it more affordable for the poor. Now the prices of life-saving drugs will be reduced from Rs.1,60,000 per month to just Rs.6,000," Y.K. Sapru, of the Mumbai-based Cancer Patients Aid Association told IANS over phone.

The apex court Monday rejected the drug maker's patent application for a major cancer drug, a ruling that allows cheap copies of important medicines to continue being distributed.

The judgment allows firms in India to continue making copycat versions of the Novartis drug Gleevec. The drugmaker argued that the drug "Glivec", as it is known in India, was a newer version that qualified for a fresh patent.

Sapru, refuting apprehensions that the ruling may be seen as a violation of patent laws, said: "If it was a violation of patent laws, then the Supreme Court wouldn't have given such a decision. It is in complete compliance with the rule of law."

Sameer Kaul, senior surgical oncologist at Indraprastha Apollo Hospitals, said the decision was a step in the right direction.

"I view this development with cautious optimism. While I am aware that we need to address the price issue of life-saving cancer drugs, we should be careful to not violate our own patent laws. The government should have stepped in much earlier to negotiate the prices with the company," Kaul told IANS.

"The government should encourage the local pharmaceutical industry to spend more on research, so that we can develop own molecules. Also, the patent time-period of 20-30 years is absurd. It should not be more than two or three years," he said.

Professor of Oncology at AIIMS, P.K. Julka, said: "The ruling is good for poor patients. It will ensure continued access to cheap drugs."


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp